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Adrenomedullin reflects cardiac dysfunction, excessive
blood volume, and inflammation in hemodialysis patients.
Background. Plasma adrenomedullin (AM) reflects cardiac
dysfunction and predicts survival after myocardial infarction.
The present study was designed to investigate whether the ma-
ture AM (mAM) reflects status of cardiac function, systemic
blood volume, or inflammation in hemodialysis patients with
cardiovascular disease, and whether mortality and additional
cardiovascular morbidity can be predicted by mAM.
Methods. Plasma levels of mAM, atrial natriuretic pep-
tide (ANP), B-type natriuretic peptide (BNP), norepinephrine
(NE), and C-reactive protein (CRP) before hemodialysis were
measured in 67 chronic hemodialysis patients with cardiovas-
cular disease, along with 2-dimensional and Doppler echocar-
diographic variables.
Results. By univariate regression analysis, mAM correlated
negatively with pulmonary venous flow velocity ratio and left
ventricular (LV) ejection fraction and positively with LV inflow
velocity ratio, LV end-diastolic, end-systolic volume indexes,
plasma CRP level, and removal fluid volume by ultrafiltration.
Multivariate stepwise regression analysis revealed that mAM
reflected all variables better than log [ANP], log [BNP], and log
[NE]. During a 1-year follow-up period, 7 patients died and 8
had additional cardiovascular events. Event-free Kaplan-Meier
curves based on the median mAM (4.55 pmol/L) showed that
patients with high plasma mAM levels had higher mortality and
morbidity than those with low plasma mAM levels (P = 0.0056).
By Cox multivariate proportional hazard analysis, mAM was
related to mortality and morbidity [hazard ratio (HR) 4.55, 95%
CI 1.2-16.8, P = 0.023).
Conclusion. Plasma mAM reflects cardiac dysfunction, ex-
cessive blood volume, and inflammation better than ANP, BNP,
and NE, resulting in a predictor of mortality and cardiovascular
morbidity in hemodialysis patients with cardiovascular disease.
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uretic peptide.
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Cardiovascular disease [1, 2], excessive blood volume
[3], and systemic inflammation [4, 5] are the major causes
of mortality in hemodialysis patients. Early diagnosis and
treatment of cardiovascular disease and excessive blood
volume and systemic inflammation may lead to improved
survival in hemodialysis patients. For this purpose, a non-
invasive biochemical testing method would be ideal to
screen for, and monitor cardiac condition, blood volume,
and inflammatory status.
Adrenomedullin (AM) was discovered in human
pheochromocytoma by monitoring its stimulating ac-
tion on platelet adenosine 3′,5′-cyclic monophosphate
(cAMP) production [6]. Immunoreactive AM has been
detected in human plasma, and human AM messenger
RNA has been reported to be highly expressed not only
in pheochromocytoma, but also in the normal adrenal
medulla, kidney, lung, cardiac ventricle, vascular en-
dothelial cells, and vascular smooth muscle cells [7]. Pre-
vious studies showed that plasma AM levels were in-
creased in left ventricular (LV) failure [8–11], myocardial
infarction [12, 13], and peripheral arterial occlusive dis-
ease [14], according to the disease severity. It has been
shown that plasma AM levels are increased in hemodial-
ysis patients [15–21], and that increased AM levels might
be involved in the regulation of systemic blood pres-
sure [16, 17, 19] and reflect systemic blood volume [15,
21] in hemodialysis patients and intracardiac pressure in
hemodialysis patients with coronary artery disease [22].
Excessive systemic blood volume before hemodialysis is
one of the potential risk factors for patient morbidity and
mortality [3]. In addition, increasing level of C-reactive
protein (CRP) is also associated with an increased risk of
death in hemodialysis patients [4, 5]. Plasma AM level has
been reported to show a significant positive correlation
with plasma CRP in patients with rheumatoid arthritis
[23], cancer, or sepsis [24], indicating that plasma AM
reflects systemic inflammatory status. Taken together,
there is a possibility that plasma AM level may predict
morbidity and mortality through the significant correla-
tion with cardiac condition, systemic blood volume, and
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inflammatory status. However, the meaning of increased
AM level in hemodialysis patients complicated with ap-
parent cardiovascular disease is not fully understood.
We hypothesized that plasma AM is a noninvasive
biochemical predictor for cardiovascular morbidity and
mortality in hemodialysis patients with cardiovascular
disease. Therefore, we conducted the present study to
investigate whether plasma AM reflects cardiac dysfunc-
tion, removal fluid volume by ultrafiltration, and systemic
inflammatory status in hemodialysis patients admitted for
evaluation of their cardiovascular disease, in comparison
with atrial natriuretic peptide (ANP), B-type natriuretic
peptide (BNP), and norepinephrine (NE), which were
previously reported as biochemical markers of LV dys-
function and predictors for mortality and cardiovascular
morbidity [25–30]. We also assessed whether subsequent
mortality and cardiovascular morbidity can be predicted
by the measurement of AM.
METHODS
Patients
Sixty-seven consecutive hemodialysis patients (48 men,
19 women; mean age 65 ± 10 years) admitted to the
National Cardiovascular Center for evaluation of their
cardiovascular disease were enrolled in the present
study. Patients complicated with atrial fibrillation, overt
pulmonary effusion, and pulmonary congestion were
excluded from the present study. All patients under-
went regular hemodialysis for 3 to 4 hours 3 times
weekly (Monday, Wednesday, and Friday). Written in-
formed consent was obtained from all patients. After re-
lease from our institute, patients were followed-up for
12 months. Subsequent cardiovascular events (new
episodes of angina, myocardial infarction, heart failure,
ventricular tachycardia, complete atrioventricular block,
transient ischemic attacks, stroke, and revascularization
of myocardial ischemia or peripheral arterial occlusive
disease) and all-cause death were accurately recorded.
Excessive intake of water, inadequate dry weight, and in-
appropriate management of electrolyte balance are com-
monly causes of heart failure in hemodialysis patients.
Thus, heart failure which had been recovered only by re-
striction of water intake, resetting of dry weight, and/or
management of electrolyte balance was excluded from
cardiovascular events in the present study.
Echocardiographic measurement
A skilled echocardiographer without knowledge of the
clinical features of the patients performed the echocar-
diographic study using a cardiac ultrasound unit (Sonos
5500; Philips Medical Systems, Andover, MA, USA) just
before hemodialysis treatment, as previously reported
[31]. LV end-diastolic volume index (LVEDVI), LV
end-systolic volume index (LVESVI), and LV ejection
fraction (LVEF) were calculated using the modified
Simpson method according to the recommendations of
the American Society of Echocardiography [32].
To assess LV diastolic function, LV diastolic filling (LV
inflow) was examined using Doppler echocardiography.
LV diastolic filling pattern was obtained with the sample
volume at the tips of the mitral valve in the apical 4-
chamber view and recorded at end-expiratory phase dur-
ing quiet breathing. Peak velocity of early diastolic filling
(E) and peak velocity of atrial filling (A) were recorded,
and the E/A ratio was calculated. The deceleration time
(DcT) was measured as the time between the top of the
E wave and the point at which the descending part of the
E wave or its asymptote crossed the zero line.
After LV inflow velocities were examined, pulmonary
venous flow velocities were obtained from the apical 4-
chamber view and recorded at end-expiration. The pulsed
Doppler sample volume was set at 0.5 to 1.0 cm into
the upper right pulmonary vein. Peak forward flow ve-
locities during ventricular systole (S) and diastole (D)
and peak reverse-flow velocity at atrial contraction (PVa)
were measured, and the S/D ratio was calculated. The du-
ration of the PVa wave (PVad) also was measured, and
the difference between duration of the mitral A wave
and pulmonary reversal wave (Ad-PVad) was calculated.
Echocardiographic parameters were obtained from 51
patients, and LV inflow velocities were obtained in 48
patients and pulmonary venous flow velocities were ob-
tained in 47 patients, because in the other patients it
proved technically difficult to evaluate these variables.
Blood pressure, excessive blood volume, blood sampling,
and assays for mAM, ANP, BNP, and NE
Blood pressure was measured with a mercury sphyg-
momanometer in the supine position after supine rest
longer than 5 minutes before blood sampling. Exces-
sive blood volume before hemodialysis was defined as
removal fluid volume by ultrafiltration during hemodial-
ysis ( = delta body weight). Blood was withdrawn through
the shunt before hemodialysis to measure mAM, ANP,
BNP, NE, and CRP and transferred into a chilled glass
tube containing disodium EDTA for NE, or a tube con-
taining disodium EDTA and aprotinin for mAM, ANP,
and BNP. The blood was centrifuged immediately at 4◦C,
and plasma was frozen and stored at −80◦C until the as-
says. The plasma NE level was measured using the stan-
dard high-performance liquid chromatography method.
Plasma levels of mAM, ANP, and BNP were measured
using specific immunoradiometric assay kits (Shionogi
Co., Ltd., Osaka, Japan), as previously reported [27, 33].
Plasma CRP level was measured using the standardized
methods in an autoanalyzer.
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Blood sampling for these humoral factors and echocar-
diographic study were performed just before hemodialy-
sis, because of the necessity to evaluate the relationship
between humoral factors and cardiac function in concur-
rence with excessive blood volume in the present study.
Statistical analysis
Data are expressed as the mean ± SD. Statistical com-
parisons were made with the Student unpaired t test or
chi-square analysis between the 2 groups. The significance
of differences between more than 2 groups was evaluated
by unpaired analysis of variance with a subsequent Fisher
multiple comparison tests. Univariate and stepwise mul-
tivariate regression analyses were used to detect indepen-
dent related factors of 2-dimensional, Doppler echocar-
diographic parameters, plasma CRP level, or removal
fluid volume among mAM, log [ANP], log [BNP], and log
[NE]. Event-free curves were estimated by the Kaplan-
Meier product-limited method and compared with the
Mantel (log-rank) test. The prognostic value of each hu-
moral factor was tested by Cox multivariate proportional-
hazards regression analysis. The median value of humoral
factors was chosen as the cutoff value (mAM 4.55 pmol/L,
ANP 230 pg/mL, BNP 442 pg/mL, NE 473 pg/mL). Differ-
ences were considered to be statistically significant when
the P value was < 0.05.
RESULTS
Clinical characteristics of the study population and
echocardiographic findings just before hemodialysis are
listed in Table 1 and Table 2, respectively. Causes of renal
failure included chronic glomerulonephritis (N = 25), di-
abetic nephropathy (N = 19), hypertensive nephrosclero-
sis (N = 9), polycystic kidney disease (N = 4), renal stone
(N = 2), renal tuberculosis (N = 1), or unknown (N = 7).
All patients had normal cardiac sinus rhythm, whereas
all patients had cardiovascular diseases, which consisted
of coronary artery disease (N = 40), peripheral arterial
occlusive disease (N = 22), hypertensive heart disease
(N = 9), cerebrovascular attack (N = 7), aortic aneurysm
(N = 6), aortic valve stenosis (N = 4), ventricular tachy-
cardia (N = 3), paroxysmal supraventricular tachycardia
(N = 1), primary pulmonary hypertension (N = 1), and
cardiac tumor (N = 1). Delta body weight ( = excessive
body fluid) was also presented in Table 1.
There was no significant difference in plasma mAM
level between the different causes of renal fail-
ure (chronic glomerulonephritis 4.77 ± 1.80; diabetic
nephropathy 4.72 ± 2.10; nephrosclerosis 4.62 ± 1.89;
polycystic kidney disease 5.33 ± 1.72; others or unknown
4.92 ± 1.31 pmol/L, P = 0.9735). There was no significant
difference in the distribution of causes of renal failure
between the classifications by E/A ratio, S/D ratio, and
Table 1. Clinical characteristics of the study population
Age years 64.7 ± 10.4
Sex Male/female 48/19
Duration of hemodialysis years 6.6 ± 8.0
Cause of renal failure number of patients
Chronic glomerulonephritis 25
Diabetic nephropathy 19
Nephrosclerosis 9
Polycystic kidney disease 4
Renal stone 2
Renal tuberculosis 1
Unknown 7
Cardiovascular disease number of events
Coronary artery disease 40
Peripheral arterial occlusive disease 22
Hypertensive heart disease 9
Cerebrovascular attack 7
Aortic aneurysm 6
Aortic valve stenosis 4
Ventricular tachycardia 3
Paroxysmal supraventricular tachycardia 1
Primary pulmonary hypertension 1
Cardiac tumor 1
Heart rate bpm 71 ± 13
Systolic blood pressure mm Hg 145 ± 22
Diastolic blood pressure mm Hg 70 ± 11
Plasma mature adrenomedullin level pmol/L 4.8 ± 1.8
Delta body weight kg 1.92 ± 1.08
Plasma C-reactive protein level mg/dL 1.15 ± 1.84
Data are expressed as number or mean ± SD.
Table 2. Echocardiographic findings just before hemodialysis
A cm/sec 103.4 ± 25.5
E cm/sec 90.6 ± 25.6
DcT msec 254.6 ± 65.9
Ad msec 145.5 ± 21.0
S cm/sec 63.6 ± 16.7
D cm/sec 47.6 ± 20.6
PVa cm/sec 26.0 ± 6.2
PVad msec 122.0 ± 18.5
E/A ratio 0.88 ± 0.23
S/D ratio 1.51 ± 0.46
Ad-PVad msec 23.1 ± 27.4
LVEDVI mL/m2 58.0 ± 21.4
LVESVI mL/m2 25.7 ± 18.1
LVEF% 59.2 ± 13.8
Abbreviations are: A, peak velocity of atrial filling; E, peak velocity of early
diastolic filling; DcT, deceleration time of early diastolic filling; Ad, duration of
atrial filling; S, peak forward-flow velocity during ventricular systole; D, peak
forward-flow velocity during ventricular diastole; PVa, peak reverse-flow velocity
at atrial contraction; PVad, duration of the PVa wave; LVEDVI, left ventricular
end-diastolic volume index; LVESVI, left ventricular end-systolic volume index;
LVEF, left ventricular ejection fraction. Data are expressed as mean ± SD.
the existence of coronary artery disease (E/A ratio P =
0.5451; S/D ratio P = 0.7806; coronary artery disease P =
0.1628).
Distribution of crude values of mAM, ANP, BNP, NE,
and CRP in patients with cardiovascular disease was
shown in Figure 1. Because plasma levels of BNP, ANP,
and NE had much greater deviations than mAM or CRP,
the clinical significance of plasma levels of BNP, ANP,
and NE was evaluated using logarithmic values.
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Fig. 1. Distribution of crude values of mAM, BNP, ANP, NE, and CRP
in patients with cardiovascular disease.
Table 3. Univariate correlation between neurohumoral factors and
echocardiographic findings in patients with hemodialysis
Age mAM Log [BNP]
R P R P R P
SBP mm Hg 0.153 0.2157 −0.366 0.0024 −0.020 0.8742
DBP mm Hg −0.155 0.2241 −0.261 0.0386 −0.183 0.1507
A cm/sec 0.234 0.1092 −0.212 0.1479 0.150 0.3086
E cm/sec −0.266 0.0593 0.270 0.0554 0.304 0.0303
DcT msec 0.350 0.0128 −0.412 0.0030 0.064 0.6605
Ad msec 0.463 0.0009 −0.253 0.082 0.024 0.8710
S cm/sec 0.069 0.6463 −0.208 0.1602 −0.510 0.0002
D cm/sec −0.231 0.1104 0.345 0.0152 0.120 0.4116
PVa cm/sec −0.030 0.8452 −0.126 0.4091 −0.466 0.0012
PVad msec 0.001 0.9934 −0.149 0.3275 −0.278 0.0646
E/A ratio −0.560 <0.0001 0.288 0.0470 0.099 0.5023
S/D ratio 0.275 0.0613 −0.465 0.0010 −0.295 0.0443
Ad-PVad msec 0.377 0.0106 −0.099 0.5191 0.287 0.0564
LVEDVI mL/m2 −0.048 0.7512 0.375 0.0095 0.227 0.1241
LVESVI mL/m2 −0.061 0.6817 0.429 0.0026 0.305 0.0369
LVEF % 0.085 0.5691 −0.392 0.0065 −0.335 0.0215
Log [ANP] Log [NE]
R P R P
SBP mm Hg 0.175 0.1569 −0.173 0.1619
DBP mm Hg 0.008 0.9482 −0.143 0.2644
A cm/sec 0.102 0.4890 0.243 0.0967
E cm/sec 0.219 0.1233 0.213 0.1326
DcT msec 0.004 0.9773 −0.028 0.8443
Ad msec −0.037 0.8045 0.054 0.7161
S cm/sec −0.338 0.0200 −0.011 0.9426
D cm/sec 0.214 0.1403 0.228 0.1150
PVa cm/sec −0.555 <0.0001 0.111 0.4696
PVad msec −0.0081 0.5956 −0.189 0.2147
E/A ratio 0.010 0.9460 −0.119 0.4218
S/D ratio −0.288 0.0499 −0.131 0.3809
Ad-PVad msec 0.103 0.5013 0.182 0.2325
LVEDVI mL/m2 0.206 0.1653 0.137 0.3578
LVESVI mL/m2 0.239 0.1051 0.279 0.0579
LVEF % −0.223 0.1321 −0.362 0.0124
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
MAM, mature adrenomedullin; BNP, B-type natriuretic peptide; ANP, atrial
natriuretic peptide; NE, nor epinephrine. For others, see Table 2.
In univariate linear regression analysis, age correlated
positively with DcT, Ad, and Ad-PVad, and negatively
with E/A ratio, whereas mAM correlated negatively with
systolic and diastolic blood pressure, DcT, S/D ratio, and
LVEF, and positively with D, E/A ratio, LVEDVI, and
LVESVI (Table 3). Log [BNP] correlated negatively with
S, PVa, S/D ratio, and LVEF, and positively with E and
LVESVI (Table 3). Log [ANP] also correlated negatively
with the S, PVa, and S/D ratio, but not left ventricular
volume indexes or LVEF (Table 3). Log [NE] correlated
negatively with only LVEF (Table 3).
We further examined the independent relationship be-
tween echocardiographic findings and humoral factors
by using stepwise multiple regression analysis. Indepen-
dent variables were selected as related factors from the
results of univariate linear regression analysis. Because
mAM was the only related factor for LVEDVI from the
results of the univariate linear regression analysis, a step-
wise multiple regression analysis was not performed for
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Table 4. Stepwise regression analyses of the DcT, E/A ratio, S/D
ratio, LVESVI, and LVEF
Independent variables Beta-coefficient P
DcT
Age 0.274 0.0409
mAM −0.353 0.0094
E/A ratio
Age −0.560 <0.0001
mAM NS
S/D ratio
mAM −0.465 0.0010
Log [BNP] NS
Log [ANP] NS
LVESVI
mAM 0.429 0.0026
Log [BNP] NS
LVEF
mAM −0.347 0.0118
Log [BNP] NS
Log [NE] −0.312 0.0224
For abbreviations, see Tables 2 and 3. NS, not significant.
Table 5. Univariate linear regression and stepwise multivariate
regression analyses between neurohumoral factors and C-reactive
protein levels and removal fluid volume in patients with hemodialysis
CRP
Univariate Multivariate
r P Beta-coefficient P
mAM 0.328 0.0067 0.328 0.0067
Log [BNP] 0.224 0.0685 NS
Log [ANP] 0.189 0.1253 NS
Log [NE] 0.225 0.0671 NS
Removal fluid volume
Univariate Multivariate
r P Beta-coefficient P
mAM 0.329 0.0066 0.329 0.0066
Log [BNP] 0.251 0.0403 NS
Log [ANP] 0.263 0.0312 NS
Log [NE] 0.016 0.8998 NS
Abbreviations are: CRP, C-reactive protein. For others, see Table 3.
LVEDVI. As listed in Table 4, mAM was independently
associated with the DcT, S/D ratio, LVESVI, and LVEF,
while NE was independently associated with LVEF.
Furthermore, in univariate and stepwise multivariate
regression analyses, plasma mAM level correlated inde-
pendently with plasma CRP level before hemodialysis
or removal fluid volume during hemodialysis better than
cardiac natriuretic peptides and NE (Table 5).
To evaluate the possible effects of LV diastolic dysfunc-
tion on the plasma mAM level, we compared the plasma
mAM level between the patients with E/A >1 and E/A
1, and between the patients with S/D <1, 1S/D<2, and
S/D2. In patients with E/A >1, the plasma mAM level
was significantly higher than those with E/A 1. Further-
more, in patients with S/D <1, the plasma mAM level was
significantly higher than the other 2 groups (Fig. 2).
To clarify the influence of coronary artery disease
(CAD) on the plasma levels of humoral factors, we sub-
divided the patients according to the presence or ab-
sence of concomitant CAD and compared the plasma
levels of humoral factors and echocardiographic find-
ings between the 2 groups. The plasma levels of mAM
and NE were comparable between the 2 groups, whereas
the ANP and BNP levels were significantly higher in
hemodialysis patients with CAD than those without
(Fig. 3). There was no significant difference in S/D
ratio, LVEDVI, and LVESVI between the 2 groups
(Fig. 4). We also compared plasma levels of ANP and
BNP between patients with CAD before coronary in-
tervention (N = 14) and after coronary intervention
(N = 12) to clarify influences of intervention therapy.
There were no significant differences in plasma ANP or
BNP levels between the 2 groups (ANP 304 ± 177 vs.
278 ± 162 pg/mL; BNP 803 ± 656 vs. 743 ± 540 pg/mL,
respectively).
During the 1-year follow-up period, 7 patients died
and 8 had additional cardiovascular events requiring hos-
pitalization (unstable angina pectoris N = 3, peripheral
arterial occlusive disease N = 3, stroke N = 2). Event-
free Kaplan-Meier curves according to the mAM cutoff
value are shown in Figure 5. The median value of mAM
(4.55 pmol/L) was used as a cutoff value in the present
study. Twelve of 33 patients with a mAM level of 4.55
pmol/L or greater, and 3 of 34 subjects with a level less
than 4.55 pmol/L experienced an episode of death and
additional cardiovascular events that led up to hospital-
ization during the follow-up periods. Patients with greater
mAM levels had a markedly greater rate of episodes
than those with lower mAM levels (log-rank test, P =
0.0056). By multivariate Cox proportional hazards re-
gression analysis, mAM was shown to be related to the
occurrence of the episodes during the follow-up periods,
whereas ANP, BNP, and NE were not (Table 6).
There was no difference in the frequency of usage con-
cerning Ca-antagonist, angiotensin-converting enzyme
inhibitor, or angiotensin II receptor blocker between
the 2 groups classified by the level of plasma mAM,
BNP, ANP, or NE (Table 7). However, the usage of
beta-blockers was more frequent in patients with higher
plasma BNP or ANP levels than the patients with lower
levels of these natriuretic peptides (Table 7).
DISCUSSION
In the present study, we showed that: (1) plasma mAM
level was negatively related to blood pressure, DcT, S/D,
and LVEF, and positively to E/A, LVEDVI, and LVESVI
in hemodialysis patients with cardiovascular disease; (2)
plasma mAM reflects LV diastolic and systolic dysfunc-
tion and LV enlargement, which were defined by de-
creases in DcT, S/D, and LVEF and increases in E/A,
LVEDVI, and LVESVI, better than natriuretic peptides
and NE; (3) plasma mAM reflects systemic inflamma-
tory status and/or removal fluid volume by ultrafiltration
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Fig. 4. Comparison of echocardiographic
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during hemodialysis better than natriuretic peptides and
NE; (4) patients with high mAM had higher mortality
and additional cardiovascular morbidity than those with
low mAM; (5) plasma ANP and BNP levels were sig-
nificantly increased in patients with CAD compared to
patients without CAD, whereas there were no significant
differences in plasma mAM levels between the 2 groups.
Plasma levels of ANP and BNP have recently been re-
ported to reflect LV mass and LV systolic dysfunction and
predict mortality in hemodialysis patients without clinical
evidence of heart failure [25–27]. Plasma NE levels have
also been reported to be associated to concentric LV hy-
pertrophy and predict mortality and cardiovascular event
morbidity in end-stage renal disease without heart failure
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Table 6. Multivariate Cox proportional hazard models for mortality
and additional cardiovascular morbidity based on humoral factors
Parameter Hazard Ratio 95% CI P
mAM 4.55 pmol/L 4.55 1.23–16.80 0.0230
BNP 442 pg/mL 1.18 0.30–4.60 0.8106
ANP 230 pg/mL 1.41 0.36–5.56 0.6218
NE 473 pg/mL 1.10 0.36–3.35 0.8655
For abbreviations, see Table 3.
Table 7. The evaluation of influences of pharmacotherapies on
plasma humoral factors
Ca-antagonist ACEI ARB Beta-blocker
Number% 41 11 18 36
mAM ≥4.55 pmol/L 17 (41) 5 (45) 7 (39) 16 (44)
mAM <4.55 pmol/L 24 (59) 6 (55) 11 (61) 20 (56)
BNP ≥442 pg/mL 21 (51) 5 (45) 7 (39) 23 (64)a
BNP <442 pg/mL 20 (49) 6 (55) 11 (61) 13 (36)
ANP ≥230 pg/mL 23 (56) 6 (55) 7 (39) 25 (69)a
ANP <230 pg/mL 18 (44) 5 (45) 11 (61) 11 (31)
NE ≥473 pg/mL 20 (49) 5 (45) 8 (44) 20 (56)
NE <473 pg/mL 21 (51) 6 (55) 10 (56) 16 (44)
Abbreviations are: ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor blocker. For others, see Table 3.
aP < 0.05 vs. another group.
[28–30]. However, there are few reports of a similar eval-
uation in hemodialysis patients with apparent concomi-
tant cardiovascular disease. In hemodialysis patients with
CAD, plasma levels of ANP and BNP have been reported
to correlate with pulmonary artery pressure, pulmonary
artery wedge pressure, LV end-diastolic pressure, LVEF,
LVEDVI, and LVESVI [34]. The plasma AM level has
been reported to be increased in patients with heart fail-
ure in association with the severity of cardiac dysfunction
[8–11], suggesting that AM might also be a useful bio-
chemical marker for the severity of heart failure. How-
ever, there are few reports concerning the significance of
the plasma AM level in hemodialysis patients with car-
diovascular disease. Thus, we evaluated the relationship
between plasma levels of these humoral factors and car-
diac conditions in hemodialysis patients with cardiovas-
cular disease. Interestingly, the plasma mAM level signif-
icantly correlated with cardiac dysfunction and LV size
better than the other humoral factors, and mAM could
be a new predictive factor of mortality and additional
cardiovascular morbidity in those patients. Osajima et al
[22] reported that mAM level is less useful than natri-
uretic peptide levels as a marker of cardiac function in
hemodialysis patients with coronary artery disease. Al-
though the exact reason for the existence of discrepancy
between the previous report and our present results is
unclear, one possibility might be the discrepancy of the
distribution of complicated cardiovascular disease. The
previous report evaluated plasma peptide levels and in-
tracardiac pressures in hemodialysis patients with coro-
nary artery disease. In contrast, our patients had 54 events
of cardiovascular disease apart from 40 coronary artery
disease, as shown in Table 1. Another possibility might be
the difference of the methods of data analysis. The pre-
vious report evaluated the clinical significance of plasma
natriuretic peptide levels using crude values of these lev-
els. In contrast, in the present study, the significance
of natriuretic peptide was evaluated using logarithmic
values.
Numerous previous studies demonstrated that the
plasma AM levels were significantly higher in patients
with end-stage renal disease than those in controls
[15–21]. AM has been reported to be involved in the
regulation of systemic blood pressure in hemodialysis
patients because the plasma AM level negatively corre-
lated with systemic blood pressure before hemodialysis
[16, 17, 19], as in the present results. Furthermore, there
are reports that mAM is a marker to evaluate circulating
blood volume in hemodialysis patients without cardio-
vascular disease [15, 21]. Although excessive blood vol-
ume causes increase of blood pressure and increased AM
level in hemodialysis patients reflects excessive systemic
blood volume, plasma AM level was negatively corre-
lated with systolic and diastolic pressure in the present
study. Taken together with the fact that AM has potent
vasodilatory action, our results supported the previous
reports that AM might be involved in the suppressive reg-
ulation of blood pressure in hemodialysis patients. In the
present study, plasma mAM level was a useful biochem-
ical marker for cardiac dysfunction and LV size better
than BNP in hemodialysis patients with cardiovascular
disease. BNP is considered to be a biochemical marker
for evaluating the severity of LV dysfunction and remod-
eling [35, 36], and the effect of specific therapy against
underlying heart disease [37]. In hemodialysis patients,
BNP has also been reported to be a marker for evaluat-
ing cardiac dysfunction and predicting overall and cardio-
vascular mortality [25, 26]. However, concomitant CAD
with end-stage renal disease causes an increase in plasma
BNP levels [19]. The increases in BNP in patients with
CAD also existed in a group with normal LV function and
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were comparable between patients who had CAD with
proximal lesions and those with distal lesions [38]. Fur-
thermore, in the present study, there were no significant
differences in plasma BNP levels between the hemodial-
ysis patients who had undergone a procedure to improve
the blood supply to the heart and those who had not. Thus,
these results suggested the possibility that the hemodial-
ysis patients with CAD might have higher plasma BNP
levels than those without CAD, despite having similar LV
function. In fact, the plasma BNP levels were significantly
higher in patients with CAD compared with the patients
without CAD, whereas there were no significant differ-
ences in plasma mAM level, S/D, LVEDVI, or LVESVI
between the 2 groups in the present study. One possible
reason for the close relationship between mAM and LV
dysfunction and LV size may be that ischemic heart dis-
ease does not affect the plasma mAM level in hemodial-
ysis patients.
Plasma mAM level was correlated negatively with DcT
and positively with E/A ratio in the present study. An
increase in E/A ratio with a decrease in DcT had been
reported to show a restrictive filling (or psuedonormal-
ized) pattern [31, 32]. Our results suggested that the
increased mAM level in hemodialysis patients with car-
diovascular disease may reflect the progression of LV di-
astolic dysfunction. Because volume overload leads to LV
dysfunction through an increase in blood pressure, LV
hypertrophy, and LV dilatation, sustained volume over-
load worsens prognosis in hemodialysis patients [3]. In-
creasing level of CRP is associated with increased risk of
death in patients undergoing long-term hemodialysis [4,
5]. Thus, the present results that plasma mAM level re-
flects not only cardiac dysfunction but also systemic blood
volume and inflammatory status better than cardiac na-
triuretic peptides might be the possible mechanism how
plasma mAM level could become a more reliable predic-
tor of cardiovascular morbidity and mortality than car-
diac natriuretic peptides.
Which organ or cell is the source of increased plasma
AM in hemodialysis patients? Previous reports demon-
strated that shear stress induces up-regulation of AM
mRNA expression in cultured human umbilical vein
endothelial cells [39], and volume overload induced by
aortocaval shunt in experimental rats increases biventric-
ular AM mRNA expression and AM peptide level [40]. In
addition, tumor necrosis factor alpha, which is one of the
most common inflammation-related cytokines, had been
reported to increase basal secretion of AM in cultured
monocyte/macrophage cell line [41]. Taken together with
these reports, our results that plasma AM level reflects
excessive fluid volume, LV dysfunction, and systemic in-
flammatory status in hemodialysis patients with cardio-
vascular disease suggest that the source of increased
plasma AM level might be cardiac ventricle, vascular en-
dothelial cells, and circulatory monocytes/macrophages.
Study limitations
We performed echocardiographic studies to evaluate
the condition of LV diastolic and systolic function and
LV size noninvasively, instead of left-sided and right-
sided catheterizations, which are more precise methods
for these evaluations. Concomitant cardiovascular dis-
ease was disproportionately distributed in the present
study. CAD was more frequent than the other cardiovas-
cular diseases. Although there was no significant differ-
ence in plasma mAM level between the different causes
of renal failure, including diabetic nephropathy, we could
not deny an influence on our results exerted by the dif-
ferent causes of renal failure. Furthermore, although high
frequency of beta-blocker usage in patients with higher
plasma natriuretic peptide levels might be due to spe-
cific pharmacotherapy against heart failure, we could not
deny an effect of the drug on the plasma natriuretic pep-
tide levels. Therefore, additional investigations should be
conducted, taking these factors into consideration.
CONCLUSION
The present results suggest that plasma mAM levels
may reflect cardiac dysfunction, excessive blood volume,
and systemic inflammation better than ANP, BNP, and
NE, resulting in a possible predictor of mortality and
additional cardiovascular morbidity in hemodialysis pa-
tients with concomitant cardiovascular disease. Further
studies are necessary to clarify the pathophysiologic role
of mAM in hemodialysis patients complicated with vari-
ous cardiovascular diseases.
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